



Clinical trial results:

A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

Summary

| | |
|--------------------------|----------------------------------|
| EudraCT number | 2016-004232-37 |
| Trial protocol | SE CZ HU BG FR DE ES BE PL SK IT |
| Global end of trial date | 13 December 2019 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 04 December 2020 |
| First version publication date | 04 December 2020 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | D5134C00003 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03354429 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | AstraZeneca AB |
| Sponsor organisation address | Södertälje, Södertälje, Sweden, SE 151 85 |
| Public contact | Information Center, AstraZeneca AB, 1 877-240-9479, Information.Center@astrazeneca.com |
| Scientific contact | Information Center, AstraZeneca AB, 1 877-240-9479, Information.Center@astrazeneca.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|----------------|-------|
| Analysis stage | Final |
|----------------|-------|

| | |
|--|------------------|
| Date of interim/final analysis | 16 January 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 13 December 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 13 December 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To demonstrate superior efficacy of ticagrelor and ASA compared with placebo and ASA in patients with acute ischaemic stroke (AIS) or TIA in the prevention of the composite of stroke and death at 30 days

Protection of trial subjects:

Patients treated with aspirin as part of standard of care. An independent data monitoring committee was responsible for safeguarding the interests of the patients by assessing the benefit/risk profile of the intervention during the study, and for reviewing the overall conduct of the study

Background therapy:

Aspirin as part of standard of care. Loading dose of 300-325 mg day 1, followed by 75-100 mg once daily

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 22 January 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------------|
| Country: Number of subjects enrolled | Argentina: 98 |
| Country: Number of subjects enrolled | Australia: 54 |
| Country: Number of subjects enrolled | Belgium: 162 |
| Country: Number of subjects enrolled | Brazil: 143 |
| Country: Number of subjects enrolled | Bulgaria: 401 |
| Country: Number of subjects enrolled | Canada: 23 |
| Country: Number of subjects enrolled | China: 1480 |
| Country: Number of subjects enrolled | Czechia: 147 |
| Country: Number of subjects enrolled | France: 444 |
| Country: Number of subjects enrolled | Germany: 192 |
| Country: Number of subjects enrolled | Hong Kong: 69 |
| Country: Number of subjects enrolled | Hungary: 692 |
| Country: Number of subjects enrolled | India: 329 |
| Country: Number of subjects enrolled | Italy: 154 |
| Country: Number of subjects enrolled | Mexico: 105 |
| Country: Number of subjects enrolled | Peru: 301 |
| Country: Number of subjects enrolled | Poland: 406 |
| Country: Number of subjects enrolled | Romania: 66 |
| Country: Number of subjects enrolled | Russian Federation: 1293 |
| Country: Number of subjects enrolled | Saudi Arabia: 27 |
| Country: Number of subjects enrolled | Slovakia: 269 |
| Country: Number of subjects enrolled | Korea, Republic of: 282 |

| | |
|--------------------------------------|---------------|
| Country: Number of subjects enrolled | Spain: 857 |
| Country: Number of subjects enrolled | Sweden: 157 |
| Country: Number of subjects enrolled | Taiwan: 248 |
| Country: Number of subjects enrolled | Thailand: 968 |
| Country: Number of subjects enrolled | Ukraine: 350 |
| Country: Number of subjects enrolled | Vietnam: 1299 |
| Worldwide total number of subjects | 11016 |
| EEA total number of subjects | 3947 |

Notes:

| Subjects enrolled per age group | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 5308 |
| From 65 to 84 years | 5312 |
| 85 years and over | 396 |

Subject disposition

Recruitment

Recruitment details:

414 study sites in 28 countries enrolled patients. The first patient was enrolled on 22 January 2018. The last patient visit took place on 13 December 2019.

Pre-assignment

Screening details:

11073 patients enrolled; 11016 patients randomised. 57 patients who were not randomised (patient did not meet inclusion/exclusion criteria n=52, patient decision n=5).

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Monitor, Carer, Data analyst, Assessor, Subject |

Arms

| | |
|------------------------------|------------|
| Are arms mutually exclusive? | Yes |
| Arm title | TICAGRELOR |

Arm description:

Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ticagrelor |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

180 mg loading dose followed by 90 mg twice daily

| | |
|------------------|---------|
| Arm title | PLACEBO |
|------------------|---------|

Arm description:

Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30

| | |
|--|-------------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo (matching ticagrelor) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Matching 180 mg loading dose followed by 90 mg twice daily

| Number of subjects in period 1 | TICAGRELOR | PLACEBO |
|---------------------------------------|------------|---------|
| Started | 5523 | 5493 |
| Completed | 5514 | 5486 |
| Not completed | 9 | 7 |
| Consent withdrawn by subject | 8 | 7 |
| Lost to follow-up | 1 | - |

Baseline characteristics

Reporting groups

| | |
|---|------------|
| Reporting group title | TICAGRELOR |
| Reporting group description: | |
| Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30 | |
| Reporting group title | PLACEBO |
| Reporting group description: | |
| Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30 | |

| Reporting group values | TICAGRELOR | PLACEBO | Total |
|---|------------|---------|-------|
| Number of subjects | 5523 | 5493 | 11016 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 2676 | 2632 | 5308 |
| From 65-84 years | 2642 | 2670 | 5312 |
| 85 years and over | 205 | 191 | 396 |
| Age Continuous Units: Years | | | |
| arithmetic mean | 65.2 | 65.1 | |
| standard deviation | ± 11.0 | ± 11.1 | - |
| Sex: Female, Male Units: Participants | | | |
| Female | 2108 | 2171 | 4279 |
| Male | 3415 | 3322 | 6737 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White | 2973 | 2948 | 5921 |
| Black or African American | 21 | 32 | 53 |
| Asian | 2353 | 2339 | 4692 |
| Native Hawaiian or other Pacific Islander | 1 | 3 | 4 |
| American Indian or Alaska Native | 173 | 168 | 341 |
| Other | 2 | 3 | 5 |

End points

End points reporting groups

| | |
|---|------------|
| Reporting group title | TICAGRELOR |
| Reporting group description: | |
| Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30 | |
| Reporting group title | PLACEBO |
| Reporting group description: | |
| Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30 | |

Primary: Composite of subsequent stroke or death

| | |
|---|---|
| End point title | Composite of subsequent stroke or death |
| End point description: | |
| Participants with subsequent stroke or death | |
| End point type | Primary |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|--|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Number of participants with event | 303 | 362 | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Prevention of the composite of stroke and death |
| Statistical analysis description: | |
| Time from randomisation to first subsequent stroke or death | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.015 ^[1] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.83 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.71 |
| upper limit | 0.96 |

Notes:

[1] - The hypothesis was tested at the 4.996% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence was used to address the issue of multiple testing

Secondary: Ischaemic stroke

| | |
|---|------------------|
| End point title | Ischaemic stroke |
| End point description: | |
| Number of participants with ischaemic stroke | |
| End point type | Secondary |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Participants with event | 276 | 345 | | |

Statistical analyses

| | |
|---|--------------------------------|
| Statistical analysis title | Prevention of ischaemic stroke |
| Statistical analysis description: | |
| Time from randomisation to first subsequent ischaemic stroke (including strokes classified as "Undetermined") | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.004 ^[2] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.79 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.68 |
| upper limit | 0.93 |

Notes:

[2] - The hypothesis was tested at the 4.996% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence was used to address the issue of multiple testing

Secondary: The modified Rankin Scale (mRS) score >1 at Visit 3

| | |
|--|---|
| End point title | The modified Rankin Scale (mRS) score >1 at Visit 3 |
| End point description: | |
| The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms, 1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. | |

Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|---------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5386 | 5333 | | |
| Units: Participants with mRS score >1 | 1282 | 1284 | | |

Statistical analyses

| | |
|---|---------------------------------|
| Statistical analysis title | Reduction of overall disability |
| Statistical analysis description: | |
| Modified Rankin Scale (mRS) score >1 at Visit 3 | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 10719 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.613 ^[3] |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0.98 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 1.07 |

Notes:

[3] - The hypothesis was tested at the 4.996% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence was used to address the issue of multiple testing

Other pre-specified: Bleeding event that fulfils SAE criteria and is categorised as GUSTO Severe

| | |
|---|---|
| End point title | Bleeding event that fulfils SAE criteria and is categorised as GUSTO Severe |
| End point description: | |
| Participants with bleeding event that fulfils SAE criteria and is categorised as GUSTO Severe | |
| End point type | Other pre-specified |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Participants with event | 28 | 7 | | |

Statistical analyses

| Statistical analysis title | GUSTO Severe bleeding |
|--|-----------------------|
| Statistical analysis description: | |
| Time from randomisation to first bleeding event that fulfils SAE criteria and is categorised as GUSTO Severe | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.001 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 3.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.74 |
| upper limit | 9.14 |

Other pre-specified: ICH or fatal bleeding event

| | |
|---|-----------------------------|
| End point title | ICH or fatal bleeding event |
| End point description: | |
| Participants with ICH or fatal bleeding event | |
| End point type | Other pre-specified |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Participants with event | 22 | 6 | | |

Statistical analyses

| | |
|---|-----------------------|
| Statistical analysis title | ICH or fatal bleeding |
| Statistical analysis description: | |
| Time from randomisation to first intracranial haemorrhage or fatal bleeding event | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.005 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 3.66 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.48 |
| upper limit | 9.02 |

Other pre-specified: Bleeding event that fulfils SAE criteria and is categorised as GUSTO Moderate/Severe

| | |
|--|--|
| End point title | Bleeding event that fulfils SAE criteria and is categorised as GUSTO Moderate/Severe |
| End point description: | |
| Participants with bleeding event that fulfils SAE criteria and is categorised as GUSTO Moderate/Severe | |
| End point type | Other pre-specified |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| | | | | |
|--------------------------------|-----------------|-----------------|--|--|
| End point values | TICAGRELOR | PLACEBO | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Participants with event | 36 | 11 | | |

Statistical analyses

| | |
|---|--------------------------------|
| Statistical analysis title | GUSTO Moderate/Severe bleeding |
| Statistical analysis description: | |
| Time from randomisation to first bleeding event that fulfils SAE criteria and is categorised as GUSTO Moderate/Severe | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Regression, Cox |

| | |
|---------------------|-------------------|
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 3.27 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.67 |
| upper limit | 6.43 |

Other pre-specified: Premature permanent discontinuation of IP due to bleeding

| | |
|---|---|
| End point title | Premature permanent discontinuation of IP due to bleeding |
| End point description: | |
| Participants with premature permanent discontinuation of IP due to bleeding | |
| End point type | Other pre-specified |
| End point timeframe: | |
| From randomisation (day 1) to visit 3 (day 30-34) | |

| End point values | TICAGRELOR | PLACEBO | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5523 | 5493 | | |
| Units: Participants with event | 152 | 32 | | |

Statistical analyses

| | |
|--|---|
| Statistical analysis title | Permanent discontinuation of IP due to bleeding |
| Statistical analysis description: | |
| Time from randomisation to premature permanent discontinuation of IP due to bleeding | |
| Comparison groups | TICAGRELOR v PLACEBO |
| Number of subjects included in analysis | 11016 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 4.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 3.28 |
| upper limit | 7.02 |

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From randomisation (day 1) up to visit 3 (day 30-34)

Adverse event reporting additional description:

Systematic assessment of serious adverse events and adverse events leading to premature permanent discontinuation of study drug. Other non-serious adverse events were not to be reported

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 22.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | Ticagrelor 90 mg bd |
|-----------------------|---------------------|

Reporting group description: -

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description: -

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only serious adverse events and adverse events leading to discontinuation of study drug were to be collected. Hence, the number of non-serious events were limited and no preferred term reached the 5% threshold.

| Serious adverse events | Ticagrelor 90 mg bd | Placebo | |
|---|------------------------|------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 571 / 5523 (10.34%) | 609 / 5493 (11.09%) | |
| number of deaths (all causes) | 36 | 27 | |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Aortic dissection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic intramural haematoma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial stenosis | | | |

| | | |
|---|------------------|------------------|
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Arteritis | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Circulatory collapse | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Haematoma | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Hypertension | | |
| subjects affected / exposed | 5 / 5523 (0.09%) | 5 / 5493 (0.09%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Hypertensive crisis | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 4 / 5493 (0.07%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Hypertensive urgency | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Hypotension | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Penetrating aortic ulcer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subclavian artery stenosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vasculitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute leukaemia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder cancer | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm malignant | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac myxoma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colorectal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Focal nodular hyperplasia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric cancer | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Glioma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cancer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung carcinoma cell type unspecified recurrent | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Malignant mediastinal neoplasm | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic gastric cancer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelofibrosis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myeloproliferative neoplasm | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian neoplasm | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pancreatic carcinoma metastatic | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Phaeochromocytoma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngeal cancer | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pituitary tumour benign | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer metastatic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal cancer | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal neoplasm | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine cancer | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Immune system disorders | | | |
| Anaphylactic reaction | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |

| | | | |
|--|------------------|------------------|--|
| occurrences causally related to treatment / all | 1 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Death | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 4 / 5493 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 4 | |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General physical health deterioration | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Necrosis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anxiety disorder | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Completed suicide | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Confusional state | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Conversion disorder | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to | 0 / 0 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| treatment / all | | | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hallucination, visual | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuropsychiatric symptoms | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Organic brain syndrome | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Panic disorder | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychotic disorder | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Somatic symptom disorder | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Endometrial hyperplasia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Menorrhagia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine haemorrhage | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Arterial bypass occlusion | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clavicle fracture | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |

| | | |
|---|------------------|------------------|
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Hip fracture | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Open globe injury | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Periprocedural myocardial infarction | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Post procedural haemorrhage | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Rib fracture | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Subdural haematoma | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Thermal burn | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Toxicity to various agents | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic intracranial haemorrhage | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Occult blood positive | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute left ventricular failure | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to | 0 / 1 | 0 / 0 | |

| | | | |
|---|-------------------|-------------------|--|
| treatment / all | | | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 5 / 5493 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Angina unstable | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve disease mixed | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 18 / 5523 (0.33%) | 15 / 5493 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 18 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Atrial tachycardia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial thrombosis | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bradycardia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac asthma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiac failure acute | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Cardiac failure congestive subjects affected / exposed | 3 / 5523 (0.05%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac ventricular thrombosis subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardio-respiratory arrest subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiomyopathy subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congestive cardiomyopathy subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease subjects affected / exposed | 2 / 5523 (0.04%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery occlusion subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracardiac thrombus subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cardiomyopathy subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve disease | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve disease mixed | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Right ventricular failure | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Sinoatrial block | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| Atrial septal defect | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 4 / 5493 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular malformation | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenopathy mediastinal | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Normochromic normocytic anaemia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Normocytic anaemia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spontaneous haematoma | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Bronchitis chronic | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 3 / 3 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epistaxis | | | |
| subjects affected / exposed | 6 / 5523 (0.11%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 4 / 6 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pneumonitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 9 / 5523 (0.16%) | 5 / 5493 (0.09%) | |
| occurrences causally related to treatment / all | 1 / 9 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Pulmonary granuloma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract haemorrhage | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Autonomic neuropathy | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Balance disorder | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain oedema | | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| Basal ganglia haemorrhage | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain stem stroke | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain stem syndrome | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid arteriosclerosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 8 / 5523 (0.14%) | 7 / 5493 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Central pain syndrome | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebellar infarction | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cerebral artery stenosis | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 2 / 4 | 2 / 3 | |
| deaths causally related to treatment / all | 2 / 4 | 1 / 2 | |
| Cerebral infarction | | | |
| subjects affected / exposed | 6 / 5523 (0.11%) | 8 / 5493 (0.15%) | |
| occurrences causally related to treatment / all | 3 / 6 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral venous sinus thrombosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral venous thrombosis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 6 / 5523 (0.11%) | 7 / 5493 (0.13%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 6 | 1 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cerebrovascular insufficiency | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic inflammatory demyelinating polyradiculoneuropathy | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia Alzheimer's type | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysgraphia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysmetria | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epilepsy | | | |
| subjects affected / exposed | 5 / 5523 (0.09%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 3 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Guillain-Barre syndrome | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 7 / 5523 (0.13%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 5 / 7 | 0 / 0 | |
| deaths causally related to treatment / all | 4 / 6 | 0 / 0 | |
| Haemorrhagic transformation stroke | | | |
| subjects affected / exposed | 8 / 5523 (0.14%) | 6 / 5493 (0.11%) | |
| occurrences causally related to treatment / all | 6 / 8 | 4 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Headache | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemianaesthesia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic encephalopathy | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|--------------------|--------------------|--|
| Hydrocephalus | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemic seizure | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracranial aneurysm | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cerebral infarction | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 6 / 5493 (0.11%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 254 / 5523 (4.60%) | 324 / 5493 (5.90%) | |
| occurrences causally related to treatment / all | 19 / 258 | 36 / 330 | |
| deaths causally related to treatment / all | 0 / 8 | 0 / 7 | |
| Lacunar stroke | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lacunar infarction | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Migraine | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neurological symptom | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paresis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinson's disease | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Partial seizures | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post stroke seizure | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychomotor hyperactivity | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Somnolence | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Status epilepticus | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Spondylitic myelopathy | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stroke in evolution | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-------------------|-------------------|--|
| Tension headache | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thalamic infarction | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 12 / 5523 (0.22%) | 30 / 5493 (0.55%) | |
| occurrences causally related to treatment / all | 0 / 12 | 3 / 31 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular dementia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral artery stenosis | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Idiopathic orbital inflammation | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Visual impairment | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| Vertigo positional | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vestibular ataxia | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticular perforation | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal ulcer haemorrhage | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspepsia | | | |

| | | |
|---|------------------|------------------|
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Dysphagia | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Gastric disorder | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Gastritis | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | |
| subjects affected / exposed | 6 / 5523 (0.11%) | 6 / 5493 (0.11%) |
| occurrences causally related to treatment / all | 5 / 6 | 3 / 6 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 |
| Gingival bleeding | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Haemorrhoidal haemorrhage | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Inguinal hernia | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 |
| Lower gastrointestinal haemorrhage | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 0 / 5493 (0.00%) |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melaena | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal haemorrhage | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal ulcer haemorrhage | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis chronic | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 3 / 3 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal ulcer haemorrhage | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 5 / 5523 (0.09%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 4 / 5 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Acute hepatic failure | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic function abnormal | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis acute | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatocellular injury | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 4 / 5523 (0.07%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cystitis haemorrhagic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| End stage renal disease | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 8 / 5523 (0.14%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 6 / 8 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy toxic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prerenal failure | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal colic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal injury | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary bladder polyp | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Urinary retention | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ecchymosis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Costochondritis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gouty arthritis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sympathetic posterior cervical syndrome | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to | 0 / 1 | 0 / 0 | |

| | | | |
|--|------------------|------------------|--|
| treatment / all | | | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus inadequate control subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic metabolic decompensation subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrolyte imbalance subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gout subjects affected / exposed | 2 / 5523 (0.04%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemia subjects affected / exposed | 3 / 5523 (0.05%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypokalaemia subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia subjects affected / exposed | 3 / 5523 (0.05%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Anal abscess subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain abscess | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 3 / 5493 (0.05%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium colitis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Endocarditis | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-------------------|-------------------|--|
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Gastrointestinal bacterial infection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 2 / 5493 (0.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infectious pleural effusion | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral discitis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella sepsis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neurosyphilis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 25 / 5523 (0.45%) | 28 / 5493 (0.51%) | |

| | | | |
|---|------------------|------------------|--|
| occurrences causally related to treatment / all | 1 / 25 | 2 / 29 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 4 | |
| Pseudomembranous colitis | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis chronic | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Sepsis | | | |
| subjects affected / exposed | 3 / 5523 (0.05%) | 5 / 5493 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Septic shock | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tracheobronchitis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tuberculosis | | | |
| subjects affected / exposed | 2 / 5523 (0.04%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 6 / 5523 (0.11%) | 7 / 5493 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 6 | 2 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection enterococcal | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 0 / 5493 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound infection | | | |
| subjects affected / exposed | 1 / 5523 (0.02%) | 1 / 5493 (0.02%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Ticagrelor 90 mg bd | Placebo | |
|---|---------------------|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 5523 (0.00%) | 0 / 5493 (0.00%) | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------|---|
| 08 May 2019 | Number of randomised subjects reduced from 13000 to 11000 |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|------|
| None |
|------|

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32668111>